articleJournal of Clinical OncologyOct 28, 2022HYBRID OA

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

GDGilberto de CastroIKIveta KudabaYWYi‐Long WuGLGilberto LopesDMDariusz M. Kowalski

Instituto do Câncer do Estado de São Paulo · Riga East University Hospital · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 5-year results from the phase III KEYNOTE-042 study (ClinicalTrials.gov identifier: NCT02220894 ). Eligible patients with locally advanced/metastatic non–small-cell lung cancer (NSCLC) without EGFR/ALK alterations and with programmed death ligand-1 (PD-L1) tumor proportion score (TPS)…

Citation impact

306
total citations
FWCI
27.56
Percentile
100%
References
8
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Pembrolizumab
  • Medicine
  • Pemetrexed
  • Carboplatin
  • Lung cancer
  • Internal medicine
  • Clinical endpoint
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding